Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.0% during the fourth quarter, according to the company in its most recent Form ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.

SG Americas Securities LLC decreased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 17.9% during the 4th quarter, according to the company in its most recent disclosure with the ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

Jim Cramer, the host of Mad Money, reflected on the uncertainty surrounding the year 2025, focusing on several macroeconomic ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...